prt2527
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT05159518)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Leukemia, B-Cell · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, T-Cell · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Myeloproliferative Disorders · Phase 1
- Neoplasms · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Prostatic Neoplasms, Castration-Resistant · Phase 1
- Sarcoma · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
Mechanism of action
- Cyclin-dependent kinase 9INHIBITOR
CDK9 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05665530 | Phase 1 | Mar 31, 2023 | Prelude Therapeutics |
| NCT05159518 | Phase 1 | Dec 31, 2021 | Prelude Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Prelude Therapeutics | For profit | 2 | 2 | 1 | 2021 |
1 organizations
Page 1 / 1